EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current Status of Cell-Based Therapies for Vitiligo

Anna Domaszewska-Szostek iD, Agnieszka Polak iD, Monika Słupecka-Ziemilska iD, Marta Krzyżanowska, Monika Puzianowska-Kuźnicka iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24043357 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Anna Domaszewska-Szostek und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Epigenetics, Mossakowski Medical Research Institute, PAS, 02-106 Warsaw, Poland. Hauptthemen laut MEDLINE: Vitiligo, Hypopigmentation. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vitiligo is a chronic pigmentary disease with complex etiology, the signs of which are caused by the destruction of melanocytes in the epidermis, leading to the lack of melanin pigment responsible for skin coloration. The treatment of vitiligo, which aims at repigmentation, depends both on the clinical characteristics of the disease as well as on molecular markers that may predict the response to treatment. The aim of this review is to provide an overview of the clinical evidence for vitiligo cell-based therapies taking into account the required procedures and equipment necessary to carry them out as well as their effectiveness in repigmentation, assessed using the percentage of repigmentation of the treated area. This review was conducted by assessing 55 primary clinical studies published in PubMed and ClinicalTrails.gov between 2000 and 2022. This review concludes that the extent of repigmentation, regardless of the treatment method, is highest in stable localized vitiligo patients. Moreover, therapies that combine more than one cell type, such as melanocytes and keratinocytes, or more than one method of treatment, such as the addition of NV-UVB to another treatment, increase the chances of >90% repigmentation. Lastly, this review concludes that various body parts respond differently to all treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VitiligoHypopigmentationHumansMelanocytesEpidermisKeratinocytesTreatment Outcome

Stichwörter der Autor:innen

cell transplantationcell-based therapieskeratinocytesmelanocytesmelanogenesisvitiligo

Autor:innen und Institutionen

  • Department of Human Epigenetics, Mossakowski Medical Research Institute, PAS, 02-106 Warsaw, Poland.
  • Faculty of Biology, University of Cambridge, Cambridge CD2 1TN, UK.
  • Division of Ophthalmology and Optometry, Department of Ophthalmology, Collegium Medicum, Nicolaus Copernicus University in Toruń, 85-168 Bydgoszcz, Poland.
  • Department of Geriatrics and Gerontology, Medical Centre of Postgraduate Education, 01-813 Warsaw, Poland.

ORCID-Profile: Anna Domaszewska-Szostek, Agnieszka Polak, Monika Słupecka-Ziemilska, Monika Puzianowska-Kuźnicka

Zitieren

APA

Domaszewska-Szostek, A., Polak, A., Słupecka-Ziemilska, M., Krzyżanowska, M., & Puzianowska-Kuźnicka, M. (2023). Current Status of Cell-Based Therapies for Vitiligo. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24043357

Vancouver

Domaszewska-Szostek A, Polak A, Słupecka-Ziemilska M, Krzyżanowska M, Puzianowska-Kuźnicka M. Current Status of Cell-Based Therapies for Vitiligo. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24043357

BibTeX
@article{DomaszewskaSzostek2023,
  author = {Domaszewska-Szostek, Anna and Polak, Agnieszka and Słupecka-Ziemilska, Monika and Krzyżanowska, Marta and Puzianowska-Kuźnicka, Monika},
  title = {Current Status of Cell-Based Therapies for Vitiligo},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24043357}
}
Kostenlos starten →